Smoke descends on Northeastern US. Map shows air quality impacts.
State officials from Maine to New York issued alerts for fine particulate matter, a toxic byproduct of wildfires that is small enough to be inhaled. Smoky conditions impacted cities including Boston and New York.
Canada's fires could produce more smoke blowing into the Northeast through the afternoon, said Brooke Taber, a National Weather Service meteorologist stationed in Burlington, Vermont. Smoke is also causing limited visibility in some areas. Wind changes could provide a respite by the night, Taber said.
Montreal had some of the worst air quality in the world due to fires in the Canadian Prairies, the Canadian Press reported, citing IQAir, a Swiss-based monitoring company. Several wildfires burning in Saskatchewan and Manitoba are sending large smoke plumes eastward, according to Quebec's fire provincial agency.
Meanwhile, New York City climbed on IQAir's list of cities with unhealthy air levels. Hazy skies and the faint smell of smoke blanketed Manhattan on Saturday.
Map shows US air quality
Why air quality matters
Officials urged people to stay indoors to reduce exposure, and to limit strenuous activity. Exposure can cause short-term effects such as irritation of the eyes, nose and throat, along with coughing, sneezing, runny nose and shortness of breath. It can be particularly dangerous for people in sensitive groups, such as children, older people and those with chronic health conditions, such as asthma or heart disease.
Canada is experiencing another harsh wildfire season in a warming climate. Dozens of wildfires are blazing uncontrolled, according to Canada's natural resources department. In early July, Manitoba's government declared a state of emergency for its historic fires.
July 17: Brace for more smoky skies as Canadian wildfires rage
Eduardo Cuevas is based in New York City. Reach him by email at emcuevas1@usatoday.com or on Signal at emcuevas.01.
This article originally appeared on USA TODAY: Air quality map shows Canandian wildfire smoke impacts
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Tropical Storm Keli forms and is second cyclone now in central Pacific Ocean
HONOLULU (AP) — A second tropical cyclone has formed in the central Pacific Ocean alongside a Category 1 hurricane. The National Hurricane Center says Tropical Storm Keli has maximum sustained winds of 40 mph (65 kph) on Monday. The storm is centered east of Hurricane Iona which formed Monday. Iona is a Category 1 hurricane. Keli is centered 1,090 miles (1,755 kilometers) southeast of Honolulu. No direct impacts from Keli are expected to affect Hawaii. THIS IS A BREAKING NEWS UPDATE. AP's earlier story follows below. HONOLULU (AP) — A hurricane that developed rapidly Monday in the central Pacific Ocean was not expected to cause any issues for Hawaii, a federal meteorologist said, as Hurricane Iona trekked west over warm, open waters. 'It's pretty high confidence that it's not going to have any direct impacts on the islands,' said Derek Wroe with the National Weather Service in Honolulu. Iona is the first named storm of the hurricane season in the central Pacific and emerged Sunday from a tropical depression to become a Category 1 hurricane in roughly a day. The hurricane is centered well south of Hawaii, however, an indirect impact will be downward pressure winds from the hurricane, creating dry and breezy conditions. 'There's a lot of upward motion in the hurricane and then there's usually compensating downward motion,' Wroe said. 'That should be the case here as well. So it will be dry, it will be breezy.' Those were the conditions that were prevalent when Hurricane Dora also passed well south of the islands in August 2023, and the associated winds led to the conditions that exacerbated the deadliest fire in the U.S. in over a century. The blaze raced through the historic town of Lahaina and resulted in the deaths of 102 people. He said there are concerns that conditions with Hurricane Iona could be at or near red flag criteria. 'That said … wouldn't be anything close to what we saw during that time with Hurricane Dora. The situation is just not that strong,' he said. The pressure gradient created by Hurricane Dora created gusts that clocked in at 50 mph (80 kph) in central Maui and well over 60 mph (96 kph) on the Big Island. There were no instruments in West Maui two years ago to measure wind. 'We don't expect anything even close to that,' he said, with possible localized gusts of over 40 mph (64 kph) with winds running around 20 mph (32 kph). On Monday, Iona was about 895 miles (1,440 kilometers) southeast of Honolulu, the U.S. National Hurricane Center in Miami said. No coastal watches or warnings were in effect. Iona is expected to strengthen more over the next couple of days before weakening around the middle of the week. The hurricane has maximum sustained winds of about 75 mph (120 kph). It was moving in a generally westward direction at about 10 mph (17 kph). A second weather system has also formed in the central Pacific. Tropical Depression Two-C is located about 1,140 miles (1,840 kilometers) east-southeast of Honolulu. Maximum sustained winds are around 35 mph (55 kph) and expected to strengthen. Wroe said he didn't expect any direct impact from this storm on Hawaii either. The administrator of the Hawaii Emergency Management Agency on Monday hosted a statewide conference call with all counties, during which the National Weather Service provided an assessment and status of the storms. 'All counties are monitoring,' agency spokesperson Kiele Amundson said in an email. Another indirect impact from these storms could be swells, but Wroe said they are relatively small and moving westward and won't create anything significant. However, a large swell is headed toward Hawaii after being generated several hundred miles east of New Zealand. It's expected to arrive in Hawaii about Thursday, about the same time the storms pass the state. 'People might wrongly attribute the swell energy to be from these tropical systems, but they're actually not,' he said. He anticipates high surf advisory to be issued for the south shores of the Hawaiian Islands, with a surf of 10 feet (3 meters) or higher. The Associated Press
Yahoo
28 minutes ago
- Yahoo
FDA Informs Sarepta That It Recommends That Sarepta Remove Its Pause and Resume Shipments of ELEVIDYS for Ambulatory Individuals With Duchenne Muscular Dystrophy
- Company commends FDA for swift and comprehensive review of available information - Shipments to sites of care will resume imminently - Sarepta and FDA will continue dialogue on next steps in the safety labeling process and risk-mitigation approach for non-ambulatory patients CAMBRIDGE, Mass., July 28, 2025--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) notified Sarepta that it may lift its voluntary pause on shipments of ELEVIDYS (delandistrogene moxeparvovec) for ambulatory patients with Duchenne. Sarepta will resume shipping ELEVIDYS to sites of care for treatment of ambulatory patients with Duchenne imminently. "Last week, at the suggestion of FDA, Sarepta made the difficult decision to pause shipments of ELEVIDYS to provide the FDA with an opportunity to complete a review of available safety information. We are very pleased that FDA chose to rapidly and comprehensively complete that review and to recommend that we remove our voluntary pause and resume shipment of ELEVIDYS for ambulatory patients. The FDA's swift review evinces a commitment to the Duchenne population, a commitment shared by Sarepta," said Doug Ingram, chief executive officer, Sarepta. "We look forward to working collaboratively with the FDA to complete the safety label update for ELEVIDYS and to discussing the approach to risk-mitigation for non-ambulatory patients, who remain on pause pending the outcome of those discussions." FDA's review of the safety data in the ambulatory population included the case of an 8-year-old in Brazil whose death was deemed unlikely to be related to treatment with ELEVIDYS by the Brazilian health authorities. FDA's investigation has concluded the death was unrelated to treatment with ELEVIDYS and confirmed that Sarepta can resume shipments. Patients and physicians can access more information about ELEVIDYS at or by calling 1-888-727-3782. ELEVIDYS is the only approved gene therapy for families and children devastated by Duchenne, a rare, progressive and ultimately fatal disease. We remain committed to working closely with the FDA to ensure that all decisions are grounded in science and the best interests of patients, considering the compelling need of these families to access disease-modifying therapy. About ELEVIDYS (delandistrogene moxeparvovec-rokl)ELEVIDYS (delandistrogene moxeparvovec-rokl) is a single-dose, adeno-associated virus (AAV)-based gene transfer therapy for intravenous infusion designed to address the underlying genetic cause of Duchenne muscular dystrophy – mutations or changes in the DMD gene that result in the lack of dystrophin protein – through the delivery of a transgene that codes for the targeted production of ELEVIDYS micro-dystrophin in skeletal muscle. ELEVIDYS is indicated for the treatment of Duchenne muscular dystrophy (DMD) in individuals at least 4 years of age. For patients who are ambulatory and have a confirmed mutation in the DMD gene For patients who are non-ambulatory and have a confirmed mutation in the DMD gene. The DMD indication in non-ambulatory patients is approved under accelerated approval based on expression of ELEVIDYS micro-dystrophin in skeletal muscle. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). IMPORTANT SAFETY INFORMATION CONTRAINDICATION: ELEVIDYS is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the DMD gene. WARNINGS AND PRECAUTIONS:Infusion-related Reactions: Infusion-related reactions, including hypersensitivity reactions and anaphylaxis, have occurred during or up to several hours following ELEVIDYS administration. Closely monitor patients during administration and for at least 3 hours after the end of infusion. If symptoms of infusion-related reactions occur, slow, or stop the infusion and give appropriate treatment. Once symptoms resolve, the infusion may be restarted at a lower rate. ELEVIDYS should be administered in a setting where treatment for infusion-related reactions is immediately available. Discontinue infusion for anaphylaxis. Acute Serious Liver Injury: Acute serious liver injury has been observed with ELEVIDYS, and administration may result in elevations of liver enzymes (such as GGT, GLDH, ALT, AST) or total bilirubin, typically seen within 8 weeks. Patients with preexisting liver impairment, chronic hepatic condition, or acute liver disease (e.g., acute hepatic viral infection) may be at higher risk of acute serious liver injury. Postpone ELEVIDYS administration in patients with acute liver disease until resolved or controlled. Prior to ELEVIDYS administration, perform liver enzyme test and monitor liver function (clinical exam, GGT, and total bilirubin) weekly for the first 3 months following ELEVIDYS infusion. Continue monitoring if clinically indicated, until results are unremarkable (normal clinical exam, GGT, and total bilirubin levels return to near baseline levels). Systemic corticosteroid treatment is recommended for patients before and after ELEVIDYS infusion. Adjust corticosteroid regimen when indicated. If acute serious liver injury is suspected, consultation with a specialist is recommended. Immune-mediated Myositis: In clinical trials, immune-mediated myositis has been observed approximately 1 month following ELEVIDYS infusion in patients with deletion mutations involving exon 8 and/or exon 9 in the DMD gene. Symptoms of severe muscle weakness, including dysphagia, dyspnea, and hypophonia, were observed. Limited data are available for ELEVIDYS treatment in patients with mutations in the DMD gene in exons 1 to 17 and/or exons 59 to 71. Patients with deletions in these regions may be at risk for a severe immune-mediated myositis reaction. Advise patients to contact a physician immediately if they experience any unexplained increased muscle pain, tenderness, or weakness, including dysphagia, dyspnea, or hypophonia, as these may be symptoms of myositis. Consider additional immunomodulatory treatment (immunosuppressants [e.g., calcineurin-inhibitor] in addition to corticosteroids) based on patient's clinical presentation and medical history if these symptoms occur. Myocarditis: Acute serious myocarditis and troponin-I elevations have been observed following ELEVIDYS infusion in clinical trials. If a patient experiences myocarditis, those with pre-existing left ventricle ejection fraction (LVEF) impairment may be at higher risk of adverse outcomes. Monitor troponin-I before ELEVIDYS infusion and weekly for the first month following infusion and continue monitoring if clinically indicated. More frequent monitoring may be warranted in the presence of cardiac symptoms, such as chest pain or shortness of breath. Advise patients to contact a physician immediately if they experience cardiac symptoms. Preexisting Immunity against AAVrh74: In AAV-vector based gene therapies, preexisting anti-AAV antibodies may impede transgene expression at desired therapeutic levels. Following treatment with ELEVIDYS, all patients developed anti-AAVrh74 antibodies. Perform baseline testing for presence of anti-AAVrh74 total binding antibodies prior to ELEVIDYS administration. ELEVIDYS administration is not recommended in patients with elevated anti-AAVrh74 total binding antibody titers greater than or equal to 1:400. Adverse Reactions: The most common adverse reactions (incidence ≥5%) reported in clinical studies were vomiting, nausea, liver injury, pyrexia, and thrombocytopenia. Report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782). For further information, please see the full Prescribing Information. About Sarepta Therapeutics Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, please visit or follow us on LinkedIn, X, Instagram and Facebook. Forward-Looking Statements This press release contains "forward-looking statements." Any statements that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believe," "anticipate," "plan," "expect," "will," "may," "intend," "prepare," "look," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements relating to our future operations, research and development programs, clinical trials, ongoing discussions and interactions with FDA, and ELEVIDYS, including the timing of resumed shipments to ambulatory patients. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: our products or product candidates may be perceived as insufficiently effective, unsafe or may result in unforeseen adverse events; our products or product candidates may cause undesirable side effects that result in significant negative consequences following any marketing approval; results from pre-clinical and early‑stage clinical trials may not be indicative of safety or efficacy in late‑stage clinical trials, and pre-clinical and clinical trials may fail to demonstrate acceptable levels of safety, efficacy, and quality of our product candidates, which could prevent or significantly delay their regulatory approval; the possible impact of regulations and regulatory decisions by the FDA and other regulatory agencies on our business; and those risks identified under the heading "Risk Factors" in our most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company, which you are encouraged to review. Any of the foregoing risks could materially and adversely affect the Company's business, results of operations and the trading price of Sarepta's common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta. We caution investors not to place considerable reliance on the forward-looking statements contained herein. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except as required by law. Internet Posting of InformationWe routinely post information that may be important to investors in the 'For Investors' section of our website at We encourage investors and potential investors to consult our website regularly for important information about us. Source: Sarepta Therapeutics, Inc. View source version on Contacts Investor: Ian Estepan617-274-4052iestepan@ Media: Tracy Sorrentino617-301-8566tsorrentino@ Kara Hoeger617-710-3898KHoeger@
Yahoo
28 minutes ago
- Yahoo
‘I depend on Depends': Deion Sanders jokes as he reveals secret bladder cancer and its aftermath
Colorado Buffaloes coach Deion Sanders revealed that he was diagnosed with an aggressive form of bladder cancer and has since had surgery to cure the disease. Sanders, 58, revealed the news Monday and joked that he now uses Depends, the absorbent underwear brand. Sanders, dressed in a cowboy hat and a pair of sunglasses, told reporters he dropped 25 pounds as he battled the disease and encouraged everybody to 'get checked out.' 'I depend on Depends, if you know what I mean,' Sanders quipped as the room laughed. 'I truly depend on Depends. I cannot control my bladder.' "If you see a Porta-Potty on the sideline, it's real,' he added. 'I'm just telling you right now, you're going to see it." Dr. Janet Kukreja, director of urologic oncology at UCHealth, told reporters Sanders had surgery to remove his bladder and create a new one. Sanders's cancer is now cured, Kukreja said as the room applauded. 'We're lucky to have found it at this stage where I could say the word cure, because I don't use that word lightly as a cancer doctor,' she said. The coach kept his diagnosis close to his chest and noted he's 'thankful' that the news didn't leak. Sanders particularly wanted to keep the news from his sons as they prepared for the NFL draft earlier this year. 'My sons, to this day, don't know what transpired,' Sanders revealed. 'I just told them something with my foot again, because I wanted them to focus on making the team and not focused on Dad.' Sanders's physicians caught his bladder cancer after he went in for a routine CT scan to check for blood clots. He encouraged others to see their doctors regularly, noting he 'probably wouldn't be sitting here today' without his medical team. 'If it wasn't for me getting tested for something else, they wouldn't have stumbled up on this,' he said. 'Make sure you go to the get the right care.' Team trainer Lauren Askevold said Sanders 'never folded one time and never wavered.' 'You couldn't ask for a better patient because he wants to get up and get going right,' she said. 'So it's been awesome. It's been a hectic journey, but there's a blessing very in disguise with all this." Sanders paused and clasped his hands as he told reporters that he's grateful for his recovery. 'It has been a tremendous journey, and I'm truly thankful that God is so good,' he said. 'God is so good. You have no idea.' This is a breaking news story. Check back for updates Solve the daily Crossword
